GlassScriptPhysician profile
Ralph Kanaan
NPI 1942493747
$1,298.01
in general payments reported to CMS, 2019-2025
20 companies · $373 in 2025
The $373 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $119 · 2021: $191 · 2022: $108 · 2023: $149 · 2024: $150 · 2025: $373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $672.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $415.72 | 2021-2025 | Arikayce, Brinsupri |
| Abbvie INC. | $140.10 | 2023-2025 | |
| Genentech USA, INC. | $122.38 | 2019-2020 | |
| Glaxosmithkline, LLC. | $83.45 | 2020-2025 | Nucala |
| Novartis Pharmaceuticals Corporation | $69.46 | 2021-2024 | |
| Gilead Sciences, INC. | $65.68 | 2021-2023 | |
| Allergan, INC. | $59.52 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.08 | 2020-2024 | Ofev |
| Genzyme Corporation | $50.06 | 2021-2023 | |
| Sunovion Pharmaceuticals INC. | $45.58 | 2019 | |
| United Therapeutics Corporation | $32.12 | 2024 | Tyvaso |
| Merck Sharp & Dohme LLC | $22.72 | 2025 | Winrevair |
| Teva Pharmaceuticals USA, INC. | $21.65 | 2021 | |
| Circassia INC. | $20.23 | 2019 | |
| Viatris Specialty LLC | $19.65 | 2025 | Yupelri |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $17.50 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.33 | 2020 | |
| Baxter Healthcare | $14.30 | 2023 | Hillrom - Life 2000 Ventilation System |
| Phadia US INC. | $14.29 | 2024 | Immunocap |
| Astrazeneca Pharmaceuticals LP | $11.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Kanaan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.